Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
•
Oncology
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
What treatment combinations be used to maximize results?
Related Questions
How have you used Hedgehog pathway inhibitors as neoadjuvant/adjuvant therapies?
Is there a general consensus on margins to use when treating SCCIS or BCC with ED&C?
How would you manage BCC to the left cheek after only half of a radiation course was completed three months ago and non-operative management is preferred?
What recommendations or protocol do you have in reducing pain when using levulan with blue light for field therapy to treat AKs?
Would you consider proceeding with a sentinel lymph node biopsy after wide excision revealed 1.2 mm residual non-ulcerated T2a melanoma on the upper back?
What factors do you weigh most heavily in the selection of radiotherapy versus topical treatments for lentigo maligna in a patient who is not a surgical candidate?
When would you offer neoadjuvant immunotherapy prior to Mohs surgery in a locally advanced squamous cell carcinoma for which clearance may require enucleation?
How should the use of the DecisionDx-Melanoma test be integrated into clinical practice to potentially avoid sentinel lymph node biopsy?
How do you manage new-onset vitiligo in a patient on immune checkpoint inhibitors?
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?